1naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
PT  - JOURNAL ARTICLE
AU  - Selewski, D.T.
AU  - Shah, G.V.
AU  - Mody, R.J.
AU  - Rajdev, P.A.
AU  - Mukherji, S.K.
TI  - Rituximab (Rituxan)
AID  - 10.3174/ajnr.A2142
DP  - 2010 Aug 01
TA  - American Journal of Neuroradiology
PG  - 1178--1180
VI  - 31
IP  - 7
4099  - http://www.ajnr.org/content/31/7/1178.short
4100  - http://www.ajnr.org/content/31/7/1178.full
SO  - Am. J. Neuroradiol.2010 Aug 01; 31
AB  - SUMMARY: Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent. FDAUS Food and Drug AdministrationFSEfast spin-echo